Tayibe Bal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tayibe Bal has a total of 287 co-authors. Here are the top co-authors by number of shared publications:
- Mehmet Çabalak
Hatay Mustafa Kemal Üniversitesi Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Hatay, Türkiye
21 shared publications - Yusuf Önlen
Department of Infectious Diseases and Clinical Microbiology, Mustafa Kemal University Medical Faculty, Hatay, Türkiye
9 shared publications - Serdar Doğan
Department of Medical Biochemistry, Faculty of Medicine, Hatay Mustafa Kemal University, Hatay, Turkey
8 shared publications - Sabahattin Ocak
Department of Infectious Disease and Clinical Microbiology, Mustafa Kemal University, Hatay, Turkey
6 shared publications - Hasibullah Yaqoobi
Department of Infectious Disease and Clinical Microbiology, Başkent University Adana Dr.Turgut Noyan Training and Research Center, Adana, Türkiye
5 shared publications - Ayse Batirel
Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Istanbul Kartal Dr. Lütfi Kırdar City Hospital, Istanbul 34865, Türkiye
4 shared publications
Latest Publications
- Open Access
- 10 April 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 37 (6) , 673-681
Efficacy and Safety of Direct-Acting Antivirals in Patients with Hepatitis C Infection: Nationwide Real-life Data from Türkiye
Background/Aims: Chronic hepatitis C virus (HCV) infection constitutes a substantial healthcare concern in Türkiye. The clinical application of direct-acting antiviral medications (DAAs) has transformed its management. The goal is to assess the efficacy and safety of DAAs in the real-world setting in Turkish patients with chronic HCV. Materials and Methods: Thirty-seven centers from Türkiye recorded 1807 patients to the database. Patients aged >18 years were enrolled to the study. Their demographics, clinical information, DAAs used, efficacy, and safety information were evaluated. Efficacy and safety results were reported for patients with 12-week post-treatment (SVR12) data. Results: Among the patients, 919 (50.9%) were female with a mean of age 56 Å} 15 years (range:18-97 years) and 238 (13%) were cirrhotic. Liver biopsy was performed in 296 patients. Mean histologic activity index score was 7.68 and fibrosis score was 2.58. Baseline mean viral load was 4.11Å~106 copies/mL. Patients received the following treatments: Paritaprevir+Ritonavir+Ombitasvir+Dasabuvir (PrOD):706, Ledipasvir+Sofosbuvir:490, Sofosbuvir+Ribavirin:176, PrOD+Ribavirin:175, Ledipasvir+Sofosbuvir+Ribavirin:156, PrO+Ribavirin:32, and PrO:10. Response at the end of treatment was 99.2% (1454/1465) and SVR12 was 97.8% (1289/1318). The DAAs were generally well tolerated. Ten and 13 patients discontinued therapy because of drug-related and unrelated adverse side effects, respectively. Conclusion: This real-world study demonstrated that DAA treatment for HCV is both safe and highly effective. In two-thirds of the patients, the hepatic inflammation is moderate to severe, and fibrosis is moderate to advanced in half of them. Patients’ characteristics suggest that HCV infection is often not diagnosed or treated until patients present with moderate-to-severe stage, indicating that diagnostic and therapeutic approaches should be used more effectively. Cite this article as: Gunduz A, .ztoprak N., Sarı ND, et al. Efficacy and safety of direct-acting antivirals in patients with hepatitis Cinfection: nationwide real-life data from Türkiye. Turk J Gastroenterol. Published online April 10, 2026. doi:10.5152/tjg.2026.25287
- 10 April 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 37 (6) , 673-681
Open AccessEfficacy and Safety of Direct-Acting Antivirals in Patients with Hepatitis C Infection: Nationwide Real-life Data from Türkiye
Background/Aims: Chronic hepatitis C virus (HCV) infection constitutes a substantial healthcare concern in Türkiye. The clinical application of direct-acting antiviral medications (DAAs) has transformed its management. The goal is to assess the efficacy and safety of DAAs in the real-world setting in Turkish patients with chronic HCV. Materials and Methods: Thirty-seven centers from Türkiye recorded 1807 patients to the database. Patients aged >18 years were enrolled to the study. Their demographics, clinical information, DAAs used, efficacy, and safety information were evaluated. Efficacy and safety results were reported for patients with 12-week post-treatment (SVR12) data. Results: Among the patients, 919 (50.9%) were female with a mean of age 56 Å} 15 years (range:18-97 years) and 238 (13%) were cirrhotic. Liver biopsy was performed in 296 patients. Mean histologic activity index score was 7.68 and fibrosis score was 2.58. Baseline mean viral load was 4.11Å~106 copies/mL. Patients received the following treatments: Paritaprevir+Ritonavir+Ombitasvir+Dasabuvir (PrOD):706, Ledipasvir+Sofosbuvir:490, Sofosbuvir+Ribavirin:176, PrOD+Ribavirin:175, Ledipasvir+Sofosbuvir+Ribavirin:156, PrO+Ribavirin:32, and PrO:10. Response at the end of treatment was 99.2% (1454/1465) and SVR12 was 97.8% (1289/1318). The DAAs were generally well tolerated. Ten and 13 patients discontinued therapy because of drug-related and unrelated adverse side effects, respectively. Conclusion: This real-world study demonstrated that DAA treatment for HCV is both safe and highly effective. In two-thirds of the patients, the hepatic inflammation is moderate to severe, and fibrosis is moderate to advanced in half of them. Patients’ characteristics suggest that HCV infection is often not diagnosed or treated until patients present with moderate-to-severe stage, indicating that diagnostic and therapeutic approaches should be used more effectively. Cite this article as: Gunduz A, .ztoprak N., Sarı ND, et al. Efficacy and safety of direct-acting antivirals in patients with hepatitis Cinfection: nationwide real-life data from Türkiye. Turk J Gastroenterol. Published online April 10, 2026. doi:10.5152/tjg.2026.25287
- Open Access
- 17 December 2025
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 37 (2) , 179-185
A National Multicenter Study on Initial Antiviral Treatment Preferences on Chronic Hepatitis B: Entecavir Versus Tenofovir Disoproxil Fumarate
Background/Aims: Selecting the initial antiviral regimen for chronic hepatitis B (CHB) requires balancing patients’ comorbidities and long-term safety. This study examines differences in patient and disease-related factors that guide clinicians to prescribe either ente cavir (ETV) or tenofovir disoproxil fumarate (TDF) as the initial treatment. Materials and Methods: The study included treatment-naïve CHB patients aged 18 or older who had been diagnosed for at least 1 year since 2010 and initiated on antiviral therapy. The data included variables such as age, gender, body mass index (BMI), comorbidities, liver disease activity, biopsy results, cirrhosis, hepatic steatosis, hepatitis B e-antigen status, hepatitis B virus DNA levels, triglycerides, cholesterol, renal function, and baseline bone mineral density (BMD), which were assessed by dual-energy x-ray absorptiometry (DEXA). Results: Among 2259 patients (61.6% male), 1270 patients (56.22%) received TDF, while 989 patients (43.78%) received ETV as firstline therapy. The TDF was more commonly prescribed to patients with a lower BMI (median
- 17 December 2025
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 37 (2) , 179-185
Open AccessA National Multicenter Study on Initial Antiviral Treatment Preferences on Chronic Hepatitis B: Entecavir Versus Tenofovir Disoproxil Fumarate
Background/Aims: Selecting the initial antiviral regimen for chronic hepatitis B (CHB) requires balancing patients’ comorbidities and long-term safety. This study examines differences in patient and disease-related factors that guide clinicians to prescribe either ente cavir (ETV) or tenofovir disoproxil fumarate (TDF) as the initial treatment. Materials and Methods: The study included treatment-naïve CHB patients aged 18 or older who had been diagnosed for at least 1 year since 2010 and initiated on antiviral therapy. The data included variables such as age, gender, body mass index (BMI), comorbidities, liver disease activity, biopsy results, cirrhosis, hepatic steatosis, hepatitis B e-antigen status, hepatitis B virus DNA levels, triglycerides, cholesterol, renal function, and baseline bone mineral density (BMD), which were assessed by dual-energy x-ray absorptiometry (DEXA). Results: Among 2259 patients (61.6% male), 1270 patients (56.22%) received TDF, while 989 patients (43.78%) received ETV as firstline therapy. The TDF was more commonly prescribed to patients with a lower BMI (median
- 9 December 2025
- Published by Elsevier in Infectious Diseases Now
- Vol. 56 (1) , 105228
Sepsis as Seen through the Eyes of AI: A Comparative evaluation of ChatGPT and Gemini
- 9 December 2025
- Published by Elsevier in Infectious Diseases Now
- Vol. 56 (1) , 105228
Sepsis as Seen through the Eyes of AI: A Comparative evaluation of ChatGPT and Gemini
- Open Access
- 28 April 2025
- Published by Izzet Baysal Training and Research Hospital in Northwestern Medical Journal
- Vol. 5 (2) , 127-131
Multiple cranial tuberculomas with meningitis and miliary tuberculosis in an immunocompetent adult
Miliary brain tuberculosis (TB) is a rare and highly lethal clinical form resulting from the extensive lymphohematogenous spread of Mycobacterium tuberculosis. Widespread brain involvement often suggests immunosuppression. However, cases have been reported in immunocompetent adults. Prognosis depends largely on prompt diagnosis and initiation of treatment. This case report presents an immunocompetent adult with miliary pulmonary TB diagnosed by bronchoalveolar lavage (BAL) fluid analysis and diffuse brain tuberculomas on brain magnetic resonance imaging (MRI).
- 28 April 2025
- Published by Izzet Baysal Training and Research Hospital in Northwestern Medical Journal
- Vol. 5 (2) , 127-131
Open AccessMultiple cranial tuberculomas with meningitis and miliary tuberculosis in an immunocompetent adult
Miliary brain tuberculosis (TB) is a rare and highly lethal clinical form resulting from the extensive lymphohematogenous spread of Mycobacterium tuberculosis. Widespread brain involvement often suggests immunosuppression. However, cases have been reported in immunocompetent adults. Prognosis depends largely on prompt diagnosis and initiation of treatment. This case report presents an immunocompetent adult with miliary pulmonary TB diagnosed by bronchoalveolar lavage (BAL) fluid analysis and diffuse brain tuberculomas on brain magnetic resonance imaging (MRI).
- Open Access
- 28 April 2025
- Published by Izzet Baysal Training and Research Hospital in Northwestern Medical Journal
- Vol. 5 (2) , 127-131
Multiple cranial tuberculomas with meningitis and miliary tuberculosis in an immunocompetent adult
Miliary brain tuberculosis (TB) is a rare and highly lethal clinical form resulting from the extensive lymphohematogenous spread of Mycobacterium tuberculosis. Widespread brain involvement often suggests immunosuppression. However, cases have been reported in immunocompetent adults. Prognosis depends largely on prompt diagnosis and initiation of treatment. This case report presents an immunocompetent adult with miliary pulmonary TB diagnosed by bronchoalveolar lavage (BAL) fluid analysis and diffuse brain tuberculomas on brain magnetic resonance imaging (MRI).
- 28 April 2025
- Published by Izzet Baysal Training and Research Hospital in Northwestern Medical Journal
- Vol. 5 (2) , 127-131
Open AccessMultiple cranial tuberculomas with meningitis and miliary tuberculosis in an immunocompetent adult
Miliary brain tuberculosis (TB) is a rare and highly lethal clinical form resulting from the extensive lymphohematogenous spread of Mycobacterium tuberculosis. Widespread brain involvement often suggests immunosuppression. However, cases have been reported in immunocompetent adults. Prognosis depends largely on prompt diagnosis and initiation of treatment. This case report presents an immunocompetent adult with miliary pulmonary TB diagnosed by bronchoalveolar lavage (BAL) fluid analysis and diffuse brain tuberculomas on brain magnetic resonance imaging (MRI).
- 4 May 2024
- Published by Elsevier in Arab Journal of Gastroenterology
- Vol. 25 (2) , 223-229
A potential new way to facilitate HCV elimination: The prediction of viremia in anti-HCV seropositive patients using machine learning algorithms
- 4 May 2024
- Published by Elsevier in Arab Journal of Gastroenterology
- Vol. 25 (2) , 223-229
A potential new way to facilitate HCV elimination: The prediction of viremia in anti-HCV seropositive patients using machine learning algorithms
- 1 April 2024
- Published by Galenos Yayinevi in Viral Hepatitis Journal
- Vol. 30 (1) , 1-6
A New Tool for the Diagnosis and Management of Viral Hepatitis: Artificial Intelligence
- 1 April 2024
- Published by Galenos Yayinevi in Viral Hepatitis Journal
- Vol. 30 (1) , 1-6
A New Tool for the Diagnosis and Management of Viral Hepatitis: Artificial Intelligence
- 22 September 2023
- Published by Bilimsel Tip Publishing House in Flora the Journal of Infectious Diseases and Clinical Microbiology
- Vol. 28 (3) , 562-568
Varicella Zoster Virus Pneumonia without Signs of Vesicular Skin and Mucosa Lesions During Pregnancy
- 22 September 2023
- Published by Bilimsel Tip Publishing House in Flora the Journal of Infectious Diseases and Clinical Microbiology
- Vol. 28 (3) , 562-568
Varicella Zoster Virus Pneumonia without Signs of Vesicular Skin and Mucosa Lesions During Pregnancy
- 25 August 2023
- Published by Caleo in Turkish Society of Clinical Biochemistry
- Vol. 21 (2) , 075-088
Relationship of Semaphorin Proteins with Blood Markers in Patients with COVID-19
Amaç: COVID salgını dünya çapında sosyo-ekonomik yaşamı ve sağlık sistemlerini etkileyen ciddi bir sağlık sorunudur. Semaforinlerin bazı hastalıklardaki rolü nispeten bilinmesine rağmen, bu moleküllerin COVID-19'un patogenezi ile ilişkisi belirsizliğini koruyor. Bu nedenle, Semaforinlerin (Sema3A, Sema4A, Sema4D ve Sema7A) biyokimyasal ve inflamatuar değişikliklerle ilişkisini ve COVID-19 hastalarında hastalık varlığını ve hastalık şiddetini öngörmedeki rollerini araştırmayı amaçladık. Gereç ve Yöntem: Bu çalışmaya toplam 144 COVID-19 hastası ve 20 sağlıklı birey dahil edildi. Serum Semaforinleri, Enzime bağlı İmmünosorbent Tahlili kullanılarak analiz edildi. Diğer laboratuvar parametreleri, rutin laboratuvar teknikleri kullanılarak ölçüldü. Bulgular: Sema3A konsantrasyonları, sağlıklı kontrollerle karşılaştırıldığında hem şiddetli hem de şiddetli olmayan COVID-19 grubundaki hastalarda yüksekti (p<0.0001). Şiddetli COVID-19 grubundaki hastalarda Sema4A seviyeleri anlamlı olarak azaldı (p=0.002). Sema3A, EOS, RBC, HGB, HCT ve MCV gibi rutin hematolojik belirteçlerle negatif korelasyon gösterdi. Ayrıca Sema3A, D-dimer ve fibrinojen gibi pıhtılaşma belirteçleri ve ESR, CRP, PCT ve ferritin gibi inflamatuar belirteçler ve ALT, AST, BUN, CK ve LDH gibi biyokimyasal belirteçler ile pozitif korelasyon göstermiştir. Sema4A, WBC ile negatif korelasyon gösterirken, LYM ve HCT ile pozitif korelasyon gösterdi. 3,03 ng/mL'nin üzerindeki Sema3A seviyeleri ve 11,8ng/mL'nin altındaki Sema4A konsantrasyonları COVID-19'un varlığını öngörebilir (sırasıyla p<0,0001, p=0,02). Sonuç: Burada sunulan verilerimiz, Sema3A ve Sema4A'nın COVID-19 için tanısal belirteçler olabileceğini ve hastalığın klinik yönetiminde önemi olabileceğini düşündürmektedir.
- 25 August 2023
- Published by Caleo in Turkish Society of Clinical Biochemistry
- Vol. 21 (2) , 075-088
Relationship of Semaphorin Proteins with Blood Markers in Patients with COVID-19
Amaç: COVID salgını dünya çapında sosyo-ekonomik yaşamı ve sağlık sistemlerini etkileyen ciddi bir sağlık sorunudur. Semaforinlerin bazı hastalıklardaki rolü nispeten bilinmesine rağmen, bu moleküllerin COVID-19'un patogenezi ile ilişkisi belirsizliğini koruyor. Bu nedenle, Semaforinlerin (Sema3A, Sema4A, Sema4D ve Sema7A) biyokimyasal ve inflamatuar değişikliklerle ilişkisini ve COVID-19 hastalarında hastalık varlığını ve hastalık şiddetini öngörmedeki rollerini araştırmayı amaçladık. Gereç ve Yöntem: Bu çalışmaya toplam 144 COVID-19 hastası ve 20 sağlıklı birey dahil edildi. Serum Semaforinleri, Enzime bağlı İmmünosorbent Tahlili kullanılarak analiz edildi. Diğer laboratuvar parametreleri, rutin laboratuvar teknikleri kullanılarak ölçüldü. Bulgular: Sema3A konsantrasyonları, sağlıklı kontrollerle karşılaştırıldığında hem şiddetli hem de şiddetli olmayan COVID-19 grubundaki hastalarda yüksekti (p<0.0001). Şiddetli COVID-19 grubundaki hastalarda Sema4A seviyeleri anlamlı olarak azaldı (p=0.002). Sema3A, EOS, RBC, HGB, HCT ve MCV gibi rutin hematolojik belirteçlerle negatif korelasyon gösterdi. Ayrıca Sema3A, D-dimer ve fibrinojen gibi pıhtılaşma belirteçleri ve ESR, CRP, PCT ve ferritin gibi inflamatuar belirteçler ve ALT, AST, BUN, CK ve LDH gibi biyokimyasal belirteçler ile pozitif korelasyon göstermiştir. Sema4A, WBC ile negatif korelasyon gösterirken, LYM ve HCT ile pozitif korelasyon gösterdi. 3,03 ng/mL'nin üzerindeki Sema3A seviyeleri ve 11,8ng/mL'nin altındaki Sema4A konsantrasyonları COVID-19'un varlığını öngörebilir (sırasıyla p<0,0001, p=0,02). Sonuç: Burada sunulan verilerimiz, Sema3A ve Sema4A'nın COVID-19 için tanısal belirteçler olabileceğini ve hastalığın klinik yönetiminde önemi olabileceğini düşündürmektedir.
- 12 July 2023
- Published by Kahramanmaras Sutcu Imam Universitesi Tip Fakultesi Dergisi in Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi
- Vol. 18 (2) , 16-21
Comparison of Patients with and without Coronavirus-19 Infection in Terms of Acquired Immune Response to Hepatitis A: A Retrospective Study
This study aimed to examine whether there is a difference in the level of immune response against hepatitis A virus between patients with and without COVID-19 infection. Fifty patients with COVID-19 disease (confirmed by PCR positivity) who were followed in our clinic between 1 June 2020 and 1 September 2020 were enrolled in this cross-sectional, retrospective, single-center study. A total of 150 patients, who had similar demographic characteristics and were randomly selected among the patients who Anti HAV IgG levels were determined during their admission to our clinic in the last two years before the pandemic (November 1, 2017-November 1, 2019) were taken as the control group. Anti-HAV IgG seropositivity rates and serum antibody titers were compared between these two groups. The median age of the 200 cases was 48.5 (25.-75. Quartiles=43.0-59.0) years, 108 (54%) were male and 92 (46%) were female. One hundred, and forty-two of the cases were 60 years and above, but the proportion of the patients aged 60 and over in the patient groups was similar (p=0.105). Although anti-HAV IgG seropositivity rates in COVID-19 patients were similar to cases in the control group (p=0.062), anti-HAV IgG titers in COVID-19 cases were found to be significantly lower than in control patients (p<0.001). Anti-HAV IgG titers were found to be significantly lower in critical COVID-19 patients (n=7) compared to other COVID-19 patients (n=43, p=0.049)(Fig 2). In addition, it was observed that there was a significant and strong correlation between the anti-HAV IgG titer and the presence of critical COVID-19 disease (η=0.988). Although our results seem to support the thesis that the presence of HAV vaccine or previous HAV infection may be protective against COVID-19 infection, especially in terms of preventing critical disease course, prospective studies with larger patient series are needed to confirm these results. Bu çalışma ile COVID-19 enfeksiyonu olan ve olmayan olgular arasında Hepatit A virüsüne karşı kazanılmış immün yanıt düzeyi açısından fark bulunup bulunmadığının irdelenmesi amaçlanmaktadır. Bu retrospektif, kesitsel, tek merkez çalışmasına kliniğimizde 1 Haziran 2020-1 Eylül 2020 tarihleri arasında COVID-19 hastalığı (PCR pozitifliği ile doğrulanmış) nedeniyle takip edilmiş 50 olgu dahil edildi. Benzer demografik özelliklere sahip olan, salgın öncesindeki son iki yılda (1 Kasım 2017–1 Kasım 2019) kliniğimize başvuruları sırasında Anti HAV IgG düzeyleri belirlenmiş olgular arasından rastlantısal olarak seçilen toplam 150 olgu ise kontrol grubu olarak alındı. Bu iki grup arasında Anti-HAV IgG seropozitiflik oranları ile serum antikor titreleri karşılaştırıldı. Çalışmaya dahil edilen toplam 200 olgunun ortanca yaşı 48.5 (IQR=43.0-59.0) yıl olup, 108’i (%54) erkek, 92’si (%46) kadındı. Olguların 142’si (%71) 60 yaş ve üzerinde idi, ancak hasta grupları içerisindeki 60 yaş ve üzeri olguların oranı benzerdi (p=0.105). COVID-19 olgularındaki Anti-HAV IgG seropozitifliği oranları kontrol grubundaki olgularla benzer olmakla birlikte (p=0.062), COVID-19 olgularındaki anti HAV IgG titrelerinin, kontrol olgularındakine göre anlamlı oranda daha düşük olduğu görüldü (p<0.001). Anti-HAV IgG titrelerinin kritik seyirli COVID-19 olgularında (n=7), diğer COVID-19 olgularına (n=43) göre anlamlı oranda daha düşük olduğu görüldü (p=0.049)(Şekil 2). Buna ek olarak anti-HAV titresi ile kritik COVID-19 hastalığı varlığı arasında anlamlı ve güçlü düzeyde bir ilişki olduğu (η=0.988) görüldü. Sonuçlarımız HAV aşısı veya geçirilmiş HAV enfeksiyonu varlığının COVID-19 enfeksiyonunda, özellikle kritik hastalık seyrinin önlenmesi açısından, koruyucu olabileceği tezini destekliyor gibi görünse de bu sonuçların doğrulanabilmesi için daha geniş hasta serilerinde yapılacak prospektif çalışmalara ihtiyaç vardır.
- 12 July 2023
- Published by Kahramanmaras Sutcu Imam Universitesi Tip Fakultesi Dergisi in Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi
- Vol. 18 (2) , 16-21
Comparison of Patients with and without Coronavirus-19 Infection in Terms of Acquired Immune Response to Hepatitis A: A Retrospective Study
This study aimed to examine whether there is a difference in the level of immune response against hepatitis A virus between patients with and without COVID-19 infection. Fifty patients with COVID-19 disease (confirmed by PCR positivity) who were followed in our clinic between 1 June 2020 and 1 September 2020 were enrolled in this cross-sectional, retrospective, single-center study. A total of 150 patients, who had similar demographic characteristics and were randomly selected among the patients who Anti HAV IgG levels were determined during their admission to our clinic in the last two years before the pandemic (November 1, 2017-November 1, 2019) were taken as the control group. Anti-HAV IgG seropositivity rates and serum antibody titers were compared between these two groups. The median age of the 200 cases was 48.5 (25.-75. Quartiles=43.0-59.0) years, 108 (54%) were male and 92 (46%) were female. One hundred, and forty-two of the cases were 60 years and above, but the proportion of the patients aged 60 and over in the patient groups was similar (p=0.105). Although anti-HAV IgG seropositivity rates in COVID-19 patients were similar to cases in the control group (p=0.062), anti-HAV IgG titers in COVID-19 cases were found to be significantly lower than in control patients (p<0.001). Anti-HAV IgG titers were found to be significantly lower in critical COVID-19 patients (n=7) compared to other COVID-19 patients (n=43, p=0.049)(Fig 2). In addition, it was observed that there was a significant and strong correlation between the anti-HAV IgG titer and the presence of critical COVID-19 disease (η=0.988). Although our results seem to support the thesis that the presence of HAV vaccine or previous HAV infection may be protective against COVID-19 infection, especially in terms of preventing critical disease course, prospective studies with larger patient series are needed to confirm these results. Bu çalışma ile COVID-19 enfeksiyonu olan ve olmayan olgular arasında Hepatit A virüsüne karşı kazanılmış immün yanıt düzeyi açısından fark bulunup bulunmadığının irdelenmesi amaçlanmaktadır. Bu retrospektif, kesitsel, tek merkez çalışmasına kliniğimizde 1 Haziran 2020-1 Eylül 2020 tarihleri arasında COVID-19 hastalığı (PCR pozitifliği ile doğrulanmış) nedeniyle takip edilmiş 50 olgu dahil edildi. Benzer demografik özelliklere sahip olan, salgın öncesindeki son iki yılda (1 Kasım 2017–1 Kasım 2019) kliniğimize başvuruları sırasında Anti HAV IgG düzeyleri belirlenmiş olgular arasından rastlantısal olarak seçilen toplam 150 olgu ise kontrol grubu olarak alındı. Bu iki grup arasında Anti-HAV IgG seropozitiflik oranları ile serum antikor titreleri karşılaştırıldı. Çalışmaya dahil edilen toplam 200 olgunun ortanca yaşı 48.5 (IQR=43.0-59.0) yıl olup, 108’i (%54) erkek, 92’si (%46) kadındı. Olguların 142’si (%71) 60 yaş ve üzerinde idi, ancak hasta grupları içerisindeki 60 yaş ve üzeri olguların oranı benzerdi (p=0.105). COVID-19 olgularındaki Anti-HAV IgG seropozitifliği oranları kontrol grubundaki olgularla benzer olmakla birlikte (p=0.062), COVID-19 olgularındaki anti HAV IgG titrelerinin, kontrol olgularındakine göre anlamlı oranda daha düşük olduğu görüldü (p<0.001). Anti-HAV IgG titrelerinin kritik seyirli COVID-19 olgularında (n=7), diğer COVID-19 olgularına (n=43) göre anlamlı oranda daha düşük olduğu görüldü (p=0.049)(Şekil 2). Buna ek olarak anti-HAV titresi ile kritik COVID-19 hastalığı varlığı arasında anlamlı ve güçlü düzeyde bir ilişki olduğu (η=0.988) görüldü. Sonuçlarımız HAV aşısı veya geçirilmiş HAV enfeksiyonu varlığının COVID-19 enfeksiyonunda, özellikle kritik hastalık seyrinin önlenmesi açısından, koruyucu olabileceği tezini destekliyor gibi görünse de bu sonuçların doğrulanabilmesi için daha geniş hasta serilerinde yapılacak prospektif çalışmalara ihtiyaç vardır.